To determine the diagnostic and/or prognostic importance of chromosomal aberrations identified in dogs with malignant (non-Hodgkin's) lymphoma, clinical stages for 6 1 dogs with lymphosarcoma were determined, the lymph node(s) were histopathologically graded, and the malignant tissue lymphocytes were karyotyped. The results from life table survival curve analysis demonstrated that first remission length and survival time were significantly longer in 15 of 6 1 (25%) dogs that had a trisomy of chromosome 13 as the primary chromosomal aberration than in those dogs (46/61, 75%) with other primary chromosomal aberrations ( P < 0.05). Sex, age, weight, histopathologic subtype and grade, World Health Organization (WHO) clinical stage, WHO and modified Karnofsky performance status, chromosomal modal number, and treatment protocol were of no prognostic importance in predicting first remission length or survival time ( P > 0.05). Multivariate analysis did not identify a significant correlation between the prognostic groups or within the various prognostic subsets (P > 0.05). The pathogenesis of canine and human non-Hodgkin's lymphoma, as observed cytogenetically, differs.
Tumors of the hematopoietic and lymphatic systems are among the most frequently recognized tumors in veterinary medicine. 48 Canine lymphosarcoma is similar in clinical presentation, histopathology, and treatment response to human non-Hodgkin's lymphoma (NHL). Canine lymphosarcoma is seen in 0.36% of all dogs presented for veterinary care and represents 83% of all canine hematologic malignancie~.'~.'~ Canine lymphosarcoma most frequently affects dogs 5-1 0 years of age but can occur at any age.15J8, 47 The multicentric form is the most common and is characterized by a generalized nonpainful lymphadenopathy with or without concurrent hepatomegaly, splenomegaly, bone marrow infiltration, or extranodal involvement. I 5 , I 8 Clinical signs of canine lymphosarcoma vary and may include lethargy, anorexia, vomiting, coughing, diarrhea, polyuria, and/or p~l y d y p s i a . '~,~~,~~ A number of reports have hypothesized that a retrovirus may be involved in the pathogenesis of canine lymphosarcoma. To date, no retroviral cause has been confirmed. However, viral particles with properties similar to those of retroviruses have been identified in short-term cultures of canine lymphosarcoma tis-
The prognosis for a dog with lymphosarcoma left sue.3. 33 untreated is poor. Survival time of untreated dogs is only 30-60 day^.^^,^^ Discussions concerning the responsiveness of canine lymphosarcoma to various treatment regimes are numerous. Unlike human NHL, no single patient characteristic in the dog has consistently been shown to be of prognostic significance for responsiveness to therapy, first remission length, or survival time. 27 A previous retrospective study of 105 dogs with naturally occumng lymphosarcoma demonstrated that sex, age, weight, World Health Organization (WHO) clinical stage, pretreatment performance status, histopathologic subtype and grade, treatment protocol, and response to treatment were of no prognostic significance for first remission length or survival time (all P > 0.05). 27 The cytogenetic evaluation of human NHL provides the physician with important diagnostic and prognostic information not available through traditional determination of clinical stage. Several chromosomal aberrations are consistently associated with specific histopathologic or immunologic subgroups, providing a more reliable diagnosis and/or prognosis. Chromosomal aberrations have been reported in the lymphocytes of dogs with lymphosarcoma; however, an insufficient number of cases have been observed to determine the diagnostic or prognostic significance of these and other reported aberrations. In previous veterinary reports, the predominate chromosomal aber-ration identified in canine lymphosarcoma has been structural with secondary numerical aberrations; however, banded chromosomal analyses were not performed. No correlation of chromosome modal number or chromosome aberration was made with histopathologic diagnosis or treatment r e s p o n~e .~, ' ,~~,~' ,~~ Knowledge regarding the pathogenesis of canine lymphosarcoma is incomplete. Canine lymphosarcoma is a widespread disease of the lymph nodes (i.e., multinodal), which is histopathologically and immunologically heterogenous. Furthermore, traditional staging and grading features (e.g., sex, age, weight, clinical stage, histopathologic subtype and grade, performance status) are of no pretreatment prognostic sig-nifi~ance.~' The hypothesis of this investigation was that in dogs with naturally occurring lymphosarcoma, specific nonrandom chromosomal aberrations occur, are identifiable karyotypically, and are of prognostic significance. If such chromosomal aberrations occur, identification of them would be invaluable to veterinarians to aid them in the diagnosis and/or prognosis of canine lymphosarcoma and to cancer researchers to study the dog as a model for human NHL.
Materials and Methods
Eighty-four dogs with multicentric lymphosarcoma were presented to the Purdue University Veterinary Teaching Hospital for treatment in the Purdue Comparative Oncology Program from June 1988 to May 199 1. Each dog was clinically evaluated prior to treatment by complete hematologic and serum biochemical analyses, thoracic and abdominal radiography, lymph node and bone marrow core biopsy and cytologic examinations, ophthalmic examination, and lymph node measurements. All lymph node biopsy specimens were reviewed histopathologically and graded by the Keil classification Clinical stages were determined for all dogs on the basis of the clinical evaluation and in accordance to World Health Organization (WHO) recommendations; all dogs were determined to be in stages III-V.63 All dogs were classified as being in WHO performance status A (i.e., physical activity not restricted with normal defecation and urination behavior) or B (i.e., physical activity restricted with abnormal defecation and urination behavior). Furthermore, dogs were classified by the modified Karnofsky performance scale as 0 (i.e., uncompromised quality of life), 1 (i.e., demonstrating clinical signs directly related to the disease without compromised quality of life), 2 (i.e., compromised quality of life with normal defecation and urination behavior), 3 (i.e., severely compromised quality of life), or 4 (Le., dead). 38 Dogs were treated by one of three available chemotherapy protocols. Most dogs were treated intravenously with either Adriamycin (doxorubicin HC1, Adria Laboratories, Columbus, OH) or Epirubicin (4'-epi-doxorubicin, Adria Laboratories) at 30 mg/m2 every 3 weeks for a maximum of six treatment cycles. Dogs that completed either the Adriamycin or Epirubicin protocol and achieved complete remission were given no further chemotherapy until relapse. At relapse, dogs were treated with either Adriamycin alone or a combination chemotherapy protocol.
A small number of dogs were treated initially'with combination chemotherapy consisting of Cytoxan (cyclophosphamide, Bristol Laboratories, Evansville, IN; 50 mg/m2 per 0s four times per week for 6 weeks, then once weekly), Oncovin (vincristine sulfate, Eli Lilly, Indianapolis, IN; 0.7 mg/ m2 intravenously once weekly for the first 6 weeks), Methotrexate (methotrexate, Lederle, Pearl River, NY; 2.5 mg/ m2 per 0s once weekly after the first 6 weeks), and 20 mg/ m2 prednisone per 0s twice daily.
Each dog was evaluated clinically for response to chemotherapy 3 weeks and 6 weeks following the onset of induction chemotherapy and classified as having progressive disease (> 50% increase in total measurable tumor volume or the presence of a new focus of neoplasia), stable disease (< 50% increase or decrease in total measurable tumor volume), partial remission (> 50% decrease in total measurable tumor volume), or complete remission (no measurable or detectable neoplasia). First remission lengths were measured from the onset of first remission to the date of relapse (or death if still in remission). Survival times were determined from the date of first chemotherapy treatment until death.
First remission length (not subsequent remission periods), survival time, and factors thought to be of possible prognostic significance (e.g., sex, age, weight, WHO clinical stage, performance status, histopathologic subtype, and chromosomal aberration[s]) were recorded for all dogs. Data collected for each prognostic factor were then divided into subsets similar to those of a previous retrospective study for statistical comparison.*' Chromosomal analysis of tissue lymphocytes obtained by incisional biopsy was done by short-term culture (72 hours) in RPMI-1640 culture medium supplemented with L-glutamine and Hepes buffer (GIBCO, Grand Island, NY). Culture media was further supplemented with 10% autologous plasma, 10% fetal calf serum (GIBCO), 1% penicillin (GIBCO), 1 Yo streptomycin (GIBCO), 0.1 Yo sodium heparin (GIBCO), 1 : 500 (v/v) pokeweed (GIBCO), 1 : 500 (v/v) phytohemagglutinin-M (GIBCO), and 1 : 200 v/v concavalin-A (Sigma, St. Louis, MO). Ten-milliliter cultures were maintained in 100-ml glass bottles at 37 C in a 5% CO, incubator. The cells were processed with common cytogenetic procedures for metaphase collection and slide preparation.'' The chromosomes were trypsin-Giemsa (GTG) banded by aging the slides for 48 hours at 60 C, incubating for 15-30 seconds in 0.3% trypsin in Dulbecco's phosphate-buffered saline (PBS, pH 6.8, GIBCO; 1 : 250 trypsin, GIBCO), and staining in Giemsa (5% in PBS) for 10 minutes.
Bright field photography of banded chromosomes was performed on a Zeiss Standard RA bright field and fluorescence microscope. A Zeiss VG9 green filter was used to enhance contrast. A Planapo 1OOx/1.3 oil Zeiss objective was used in conjunction with a bright field condensor. Kodak T-Max 100 film provided the best reproduction of band resolution. Negatives of selected metaphase cells were hand developed and enlarged onto a photographic stand and developed onto Kodak Polycontrast I11 paper using a no. 3 contrast filter.
Because no standard recommendations for the arrange- of nomenclature regarding human cancer cytogenetic aberr a t i o n~.~~ Preliminary cytogenetic analysis of malignant canine metaphase lymphocytes revealed that all cells contained at least one or more chromosomal aberrations. The time and effort necessary to perform karyotype analysis by hand on such a large number of cells over a large population of dogs was considered impractical. Therefore, to identify the primary chromosomal aberration from a population of malignant canine lymphocytes, two assumptions were made. First, it was assumed that the chromosomal modal number population of cells originated in the primary neoplastic clone. Second, it was assumed that the primary chromosomal aberration was identifiable from this restricted population of metaphase cells. Briefly, the chromosomal modal number was determined from those evaluable G-banded metaphase cells (i.e., having minimal chromosomal overlap and uniform trypsinization of chromosomes), which were selected from no less than 20 randomly selected coordinates from two microscope slides. From the modal number population (i.e., the primary neoplastic clone), chromosomal aberrations were identified by microscopic visualization and recorded using standard nomenclature established by the Pans Conference on Human Cyt~genetics.~'
To determine if an identified chromosomal aberration was pathologic rather than artifactual in origin, sequential sampling statistical analysis was performed.I6 Sequential sampling tables establish an upper limit to the frequency of chromosomal aberrations that would be expected to occur from technical factors (e.g., medium pH, medium supplementation) and a lower limit to the frequency of chromosomal aberrations that would indicate true chromosomal aberrations. In this study, to define a chromosomal aberration as pathologic, it had to be identified in a minimum of three metaphase cells from a minimum sample size of 17 metaphase cells. These acceptance numbers were derived from a sequential sampling analysis table with a type I error of 5% (i.e., probability of identifying an artifactual chromosomal aberration as pathologic) and a type I1 error of 10% (probability of identifying a pathologic chromosomal aberration as artifactual).I6 For each dog, the primary chromosomal aberration was determined to be the chromosomal aberration occumng with the highest frequency from the modal number population and also determined to be pathologic by sequen-tial sampling statistical analysis (i.e., nonrandom and specific). The most representative metaphase cell demonstrating the primary chromosomal aberration was photographed for subsequent karyotype production and analysis.
Life table survival curve and multivariate analyses were performed to determine if differences in first remission length or survival time existed between the subsets of each possibly prognostic category using the Kaplan-Meier life table method (SASR programs for analysis).78 Differences in survival curves between dogs grouped according to the factor being evaluated were tested by the Wilcoxon and Log rank Multivariate analysis was performed as part of the life table analysis function to test for any possible correlation (i.e., interaction) among the dependent variables (e.g., sex, age, weight, etc.) obtained from the same experimental unit (i.e., dog) when compared with the same independent variable (e.g., first remission length, survival time).78
Results
Eighty-four dogs with lymphosarcoma were prospectively entered into this investigation, but only 6 1 had complete clinical staging, histopathologic grading, and cytogenetic data for analysis (Table 1 ). Male and female dogs were equally represented. Most dogs were between 6 and 10 years of age and of different body weights. The majority of dogs presented in advanced clinical stage (IV and V) and high histopathologic grade (centroblastic).
The results of G-banded cytogenetic analysis are provided in Table 2 . The chromosomal modal number ranged from 71 to 85 chromosomes. From the modal population of metaphase cells, a primary aberration was identified and determined to be of histopathologic importance (i.e., nonrandom and specific) by sequential sampling analysis in all 61 dogs. Of the primary aberrations, 18 dogs had a reciprocal chromosomal translocation resulting from the centric fusion of two acrocentric chromosomes, 15 dogs had a trisomy of chromosome 13, nine dogs had a monosomy of chromosome 15, six dogs had a trisomy of chromosome 34, three dogs had a trisomy of chromosome 36, three dogs had a monosomy of chromosome 8, two dogs had a monosomy of chromosome 16, one dog had a monosomy of chromosome 27, one dog had a monosomy of chromosome 14, one dog had a monosomy of chromosome 11, one dog had a trisomy of chromosome 30, and one dog had a deletion of band 12 on chromosome 5. Most secondary chromosomal aberrations were nonspecific numerical aberrations. A representative karyotype demonstrating monosomy of chromosome 15 as the primary chromosomal aberration is illus~rated in Fig. 1 .
First remission lengths and survival times for each prognostic category by subset are summarized in Table  1 . Life table analysis indicated that first remission length and survival time were significantly longer (P < 0.05) * Values reported were generated by life table analysis using the log-rank test for homogeneity between the distribution response curves t Comparison of only the first three listed subsets. obtained from those subsets within a strata that contained five or more dogs.
in dogs diagnosed with a trisomy of chromosome 13 as the primary aberration than in dogs diagnosed with other primary aberrations. Also, first remission length and survival time were significantly longer in those dogs that received more than five treatments with either Adriamycin or Epirubicin ( P < 0.05 
Discussion
The human karyotype in health and disease has been and continues to be the focus of close scrutiny in oncology research. There are two major reasons to study the chromosomes of tumors: to determine the signif- 2  29  29  18  3  5  7  20  20  3  42  33  0  27  22  18  0  17  0  26  22  3  3  52  12  0  18  18  46  3  25  1  7  35  7   24  33  29  17  18  25  22  33  57  23  40  28  56  37  45  37  35  37  36  21  21  21  32  30  27  27  54  47  22  30  31  23  30  31  21  26  31  46  42  74  66  33  33  29  66  42  39  18  22  43  32   79  75  78  81  85  75  78  80  81  78  77  78  77  80  74  76  73  85  80  79  76  78  77  81  82  76  80  82  77  82  80  81  71  79  77  80  79  77  77  81  78  77  79  80  83  72  79  76  78  84 icance of structural and/or numerical chromosomal aberrations in the pathogenesis of neoplastic transformation and to utilize this knowledge for proper health care decisions (i.e., diagnosis and/or progn~sis).~' Correlation of cytogenetic findings to histopathologic and immunologic data in humans with NHL are complicated because of the various histopathologic classification systems used by pathologists. Further confusion is created by the grouping of histopathologic subtypes of NHL into prognostic categories (grades) based upon survival time. A low grade corresponds to a histopathologic subtype of human NHL that has been associated with a significantly longer survival time than those cases presenting with a high-grade NHL histopathologic subtype. Chromosomal aberrations are nonrandom in human NHL, and several aberrations are consistently associated with histopathologic grade^.'^ Approximately 80-95% of human NHL specimens yield sufficient numbers of informative metaphases, and 76-1 00% have clonal karyotypic abnor-malitie~.'~ The cytogenetic and molecular genetic pathogenesis of Burkitt's lymphoma, a high-grade human NHL, has been extensively i n~e s t i g a t e d .~~
The majority of cases have a clonal abnormality involving a translocation of an immunoglobulin gene (e.g., chromosome 14q heavychain immunoglobulin, chromosome 22q light-chain immunoglobulin) to the long arm of chromosome 8.8, 69 The myc oncogene is located at chromosome 8q24 and is commonly involved in the translocation Sequences of the rnyc gene are brought into close as- The G-banded karyotype shows that primary aberration was a monosomy of chromosome 15. The final karyotype for this dog was 82XX;mon(3, 7, 11, 15, 23)tn(4, 9, 17, 22, 24, 26, 28, 31, 33) . sociation with the transcription enhancement region of the immunoglobulin gene.2o The myc gene is inappropriately transcribed, resulting in neoplastic transformation.61 This event appears to be very important in the pathogenesis of Burkitt's l y m p h~m a .~J Although clinical staging and histopathologic grading are important factors in predicting first remission length and survival time in human NHL, their predictive value has not been well defined for canine lymp h o~a r c o m a ,~~ and conflicting reports exist in the veterinary l i t e r a t~r e . '~,~~,~~,~~ The normal canine lymph node is subdivided into nodules containing homogeneous populations of lymphocytes. In contrast, the canine lymph node with lymphosarcoma is normally densely packed, displacing the normal nodal architec-ture, and is histopathologically heterogeneous. l 2 Although the cellular structure is similar in canine and human NHL, the histopathologic schemes of prognostic significance in humans (e.g., Rappaport, Keil, Lukes-Collins, NCIWF) have not conclusively been of prognostic utility in the dog,10,12,13,24,2s,27,81,90 because human classification schemes rely heavily upon nodal architecture and/or immunophenotype, whereas canine lymphosarcomas usually present with complete effacement of normal nodal architecture and are immunologically heterogeneou~.~~,'~ The conclusion reached in this clinical, histopathologic, and cytogenetic prospective review of canine lymphosarcoma were that 1) traditional methods used in the routine clinical evaluation of human NHL (e.g., sex, age, weight, histopathologic subtype and grade, WHO clinical stage, performance status) are of no prognostic significance in canine lymphosarcoma (P > 0.05) and 2) first remission length and survival time were significantly longer (P < 0.05) in those dogs having a trisomy of chromosome 13 as the primary chromosomal aberration, having a complete response to anticancer chemotherapy at either day 21 or day 42 following treatment initiation, or able to complete six treatment cycles with an anthracycline chemotherapeutic agent.
In contrast to epithelial neoplasms, in which histopathologic features appear to persist in a relatively stable form throughout the course of illness, hematopoietic and lymphoid neoplasms frequently have striking changes in their structural appearance. Such changes are manifest as a mixture of neoplastic, reactive, dividing, differentiating, and normal cell^.^^,^^ Early undiagnosed phases of lymphosarcoma in the dog may be as histopathologically and immunologically diverse as those of human NHL; however, by the time of presentation to a veterinarian for diagnosis, most canine lymphosarcomas are of similar clinical stage and histopathologic and/or immunologic grade. 25 In this investigation, 44 of 61 dogs were presented with advanced clinical stage and 41 of them were of high histopathologic grade. The clinical and histopathologic findings for these dogs are representative of other reported studies of lymphosarcoma. The uniformity of these observations may explain why traditional clinical staging and histopathologic grading methods fail to serve as prognostic features for the dog.
Cancer is the result of the accumulation of multiple genetic changes.56 Each alteration, whether an initiating or a progression-associated event, may be mediated through a gross chromosomal change and therefore has the potential to be cytogenetically visible. Although the mechanisms whereby neoplastic cells become less genetically stable and develop specific, nonrandom chromosomal aberrations are poorly understood, it has been hypothesized that some neoplasia-producing mutations may inactivate a repair locus, as one of many pleotrophic effects, thus facilitating later numerical and structural karyotypic change^.^*-^^-^^ Conversely, another hypothesis is that the persistence of the carcinogen in the tumor or simply a nutritional insufficiency in the microenvironment might predispose aberrant cellular division. 93 It follows then that shifts in the balance between the genetic instability of an expanding tumor cell population and the selection pressure that some of the cells confront might lead to an increased or decreased genetic heterogeneity within the tumor.
In human NHL studies, primary chromosomal aberrations tend to be structural and correlate with histopathologic and immunologic grading and are of prognostic significance for remission length and survival time.2'. 37.41.42,75.77 In the 61 dogs evaluated in this investigation, the primary chromosomal aberrations were numerical ( n = 42) rather than structural (n = 19), did not correlate with other prognostic categories (e.g., his-topathologic grade), but were predictive for first remission length and survival time (P < 0.05). These results and those of this and previous canine cytogenetic investigations indicate that the pathogenesis of human NHL and canine lymphosarcoma, as observed cytogenetically, differs. Specifically, whereas the initiating event in the pathogenesis of human NHL is a reciprocal translocation of chromosomal material resulting in the overexpression of an immunoglobulin gene, the initiating event in the pathogenesis of canine lymphosarcoma is more likely to be a chromosomal segregation error resulting in gene amplification.
The first argument that may be used to support this hypothesis is that the autosomes of the family Canidae demonstrate remarkable structural stability as compared with human autosomes. When compared with autosomes of other carnivores, canine autosomes are unique in that they have little to almost no constitutive h e t e r~c h r o m a t i n .~~.~~,~' Constitutive heterochromatin is rich in highly repetitive DNA sequences, replicates in late S phase, and tends to be localized in the centromeric portion of the c h r o m~s o m e .~ The significance of the low amount or complete lack of constitutive heterochromatin in the dog is not completely known; however, in other species (e.g., humans) karyotypic changes (e.g., translocations, deletions, rearrangements) occur more frequently at centromeric locations rich in constitutive hetero~hromatin.~~ This may reflect the high degree of G-banding conservatism with other members of the family Canidae and the low frequency of structural chromosomal aberrations (i.e., translocations) observed in the domestic dog. 87, 88, 94 The second argument that may be used to support the hypothesis that the pathogenesis of human and canine lymphosarcoma differs is that structural aberrations that are initiated as chromatid or chromosomal breaks and then reform as reciprocal and/or nonreciprocal translocations (i.e., excluding centric fusions) have not been reported in the dog. Including those in this report, a total of 139 neoplastic and nonneoplastic structural chromosomal aberrations have been reported in the dog, and all but one (dog no. 13) have been acrocentric autosomal centric fusions resulting in the formation of a novel metacentric chromois common for cell lines, after multiple passages, to develop centric fusions among acrocentric chromos o m e~.~~ In vivo neoplastic cell populations are exposed to passage conditions similar to those of in vitro cell populations (e.g., nutrient deprivation during rapid cellular proliferation then nutrient supplementation following tumor angiogenesis) and therefore are as likely to develop similar autosomal acrocentric centric fus i o n~.~,~ The multiple centric fusions previously observed in the canine transmissible venereal tumor would support this conclusion. 1, 5, 59, 62, 70, 85, 89 Additionally, none of the reciprocal chromosomal translocations (i.e., presumably centric fusions) in the 18 dogs evaluated in this investigation were of similar origin, suggesting that this aberration, although of high frequency, was the result of a passage phenomenon within the malignant lymph node and not reflective of the true primary (i.e., numerical) chromosomal aberration.
Numerical chromosomal aberrations are a general feature of most human solid tumors and some hematopoietic tumors and are almost always of prognostic s i g n i f i c a n~e .~.~~-~~ They are hypothesized to occur via abnormal chromosomal disjunction (e.g., anaphase lag), resulting in the deletion, duplication, or amplification of whole chromosomes or chromosome segm e n t~.~,~~.~~,~~ Numerical aberrations (primary or secondary) may result in low-or high-level gene amplification with functionally distinct physiological effects.34 When a gene is replicated, the amount of gene transcription is doubled. With a constant rate of mRNA some. 1.5.1 I , 14,19.22,23,26,28,29,43,46,5~55,59,62,65,68,70,80,84,85,89,9l . 92 It translation, the amount of gene product is also doubled, resulting in an increased gene dosage. Minor changes in gene dosage, brought on by the loss or acquisition of one or two extra copies of a chromosome or chromosome arm, could critically affect the cell cycle.34.60 Increased gene dosage of one or more loci may explain the prognostic difference observed between those dogs having a primary chromosomal aberration identified as a monosomy of chromosome 1 5 and those dogs having a trisomy of chromosome 13.
In conclusion, canine lymphosarcoma presents as a widespread disease of the lymph node (i.e., multinodal), which is histopathologically and immunologically heterogenous. In this investigation, specific nonrandom chromosomal aberrations were identified in 61 dogs with naturally occurring lymphosarcoma. These aberrations were predominantly numerical rather than structural and, within the treatment parameters defined, were of prognostic significance for first remission length and survival time (P < 0.05). Once therapy was initiated, clinical response at 2 1 days and 42 days was also of prognostic significance for first remission length and survival time (P < 0.05). Longer first remission lengths and survival times were also noted when dogs were given more than five treatments with either Adriamycin or Epirubicin chemotherapy (P < 0.05). Other traditional clinical staging and histopathologic grading features (e.g., sex, age, weight, clinical stage, histopathologic subtype and grade, performance status) were of no pretreatment prognostic significance (P > 0.05).
Knowledge regarding the pathogenesis of canine lymphosarcoma is incomplete. The identification of a specific nonrandom chromosomal aberration is the first step in the isolation and identification of a gene or gene product that may be involved in the pathogenesis of this neoplastic disorder. Future considerations include further cytogenetic, histopathologic, immunologic, flow cytometric, and molecular biologic characterization of canine lymphosarcomas at the time of diagnosis to specifically identify those genes or gene products responsible for lymphoma initiation and/or progression.
